CLINICAL TRIALS PROFILE FOR IVERMECTIN
✉ Email this page to a colleague
505(b)(2) Clinical Trials for ivermectin
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| New Indication | NCT05283954 ↗ | Use of a Combined Regimen of Fluoxetine, Prednisolone and Ivermectin in the Treatment of Mild COVID-19 to Prevent Disease Progression Progression in Papua New Guinea | Not yet recruiting | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia | Phase 2/Phase 3 | 2022-05-01 | The Fluo-Pred-Iver clinical trial will test the efficacy of a combined regimen of Fluoxetine, Prednisolone and Ivermectin (Fluo-Pred-Iver), as treatment for ambulatory patients with mild COVID-19. The overarching idea of the work proposed herein is to investigate the use of Fluo-Pred-Iver to treat COVID-19, conducting a randomized controlled clinical trial to evaluate a new indication for these widely available drugs. It is estimated to include 954 participants. |
| New Indication | NCT05283954 ↗ | Use of a Combined Regimen of Fluoxetine, Prednisolone and Ivermectin in the Treatment of Mild COVID-19 to Prevent Disease Progression Progression in Papua New Guinea | Not yet recruiting | National Department of Health, Papua New Guinea | Phase 2/Phase 3 | 2022-05-01 | The Fluo-Pred-Iver clinical trial will test the efficacy of a combined regimen of Fluoxetine, Prednisolone and Ivermectin (Fluo-Pred-Iver), as treatment for ambulatory patients with mild COVID-19. The overarching idea of the work proposed herein is to investigate the use of Fluo-Pred-Iver to treat COVID-19, conducting a randomized controlled clinical trial to evaluate a new indication for these widely available drugs. It is estimated to include 954 participants. |
| New Indication | NCT05283954 ↗ | Use of a Combined Regimen of Fluoxetine, Prednisolone and Ivermectin in the Treatment of Mild COVID-19 to Prevent Disease Progression Progression in Papua New Guinea | Not yet recruiting | Oriol Mitja | Phase 2/Phase 3 | 2022-05-01 | The Fluo-Pred-Iver clinical trial will test the efficacy of a combined regimen of Fluoxetine, Prednisolone and Ivermectin (Fluo-Pred-Iver), as treatment for ambulatory patients with mild COVID-19. The overarching idea of the work proposed herein is to investigate the use of Fluo-Pred-Iver to treat COVID-19, conducting a randomized controlled clinical trial to evaluate a new indication for these widely available drugs. It is estimated to include 954 participants. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for ivermectin
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00127504 ↗ | Clinical Trial of Rifampin and Azithromycin for the Treatment of River Blindness | Completed | Universidad del Valle, Guatemala | Phase 2 | 2003-07-01 | The purpose of this study is to determine whether rifampin and/or azithromycin are effective in the treatment of river blindness (onchocerciasis). |
| NCT00127504 ↗ | Clinical Trial of Rifampin and Azithromycin for the Treatment of River Blindness | Completed | University of Alabama at Birmingham | Phase 2 | 2003-07-01 | The purpose of this study is to determine whether rifampin and/or azithromycin are effective in the treatment of river blindness (onchocerciasis). |
| NCT00127504 ↗ | Clinical Trial of Rifampin and Azithromycin for the Treatment of River Blindness | Completed | Centers for Disease Control and Prevention | Phase 2 | 2003-07-01 | The purpose of this study is to determine whether rifampin and/or azithromycin are effective in the treatment of river blindness (onchocerciasis). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ivermectin
Condition Name
Clinical Trial Locations for ivermectin
Trials by Country
Clinical Trial Progress for ivermectin
Clinical Trial Phase
Clinical Trial Sponsors for ivermectin
Sponsor Name
